Life Science Investing "LEQEMBI®" for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Life Science Investing Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society Annual Meeting
Life Science Investing Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease Conference 2025
Life Science Investing Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease Conference 2025
Life Science Investing New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025 Confirms Pharmacological Effect of LEQEMBI® on Neurotoxic A? Protofibrils in CSF
Life Science Investing New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025 Confirms Pharmacological Effect of LEQEMBI® on Neurotoxic A? Protofibrils in CSF
Life Science Investing Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Life Science Investing Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Life Science Investing Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Life Science Investing Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference
Life Science Investing High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Life Science Investing "LEQEMBI®" IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Life Science Investing Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology Kidney Week 2025
Life Science Investing Health Canada Grants Authorization for "LEQEMBI®" for the Treatment of Early Alzheimer's Disease
